Artificial intelligence (AI) is transforming the pharmaceutical industry, with AI-designed drugs anticipated to commence clinical trials by 2026.
“AI applied to science is a lot richer than just the language models,” Google DeepMind CEO Demis Hassabis and the founder of Isomorphic Labs during a panel at the World Economic Forum in Davos, Switzerland, on Tuesday.
“We’ll hopefully have some AI-designed drugs in the clinic by the end of the year. That’s the plan,” he added.
Notably, Isomorphic Labs, a subsidiary of Alphabet, is scheduled to initiate trials for an AI-designed drug by the end of this year, targeting significant health concerns such as oncology, cardiovascular disorders, and neurodegenerative diseases.
Additionally, Retro Biosciences, supported by OpenAI’s CEO Sam Altman, is undertaking efforts to secure $1 billion in funding to expand human lifespan by a decade. […]
— Read More: endtimeheadlines.org
